– In response to global clients’ increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance and drug product in Germany – The investment promotes the creation of additional high-skilled jobs – As part of WuXi Biologics’ global manufacturing network, a new drug product fill line is being installed at … Read more
DUNDALK, Ireland, May 22, 2023 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category. WuXi Biologics was recognized for using innovative … Read more
DUNDALK, Ireland, May 22, 2023 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category. WuXi Biologics was recognized for using innovative … Read more
WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April 2023. WuXi Biologics will leverage its global manufacturing network and dual-sourcing strategy to support InflaRx in … Read more